Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis
- PMID: 27820614
- DOI: 10.1001/jamainternmed.2016.6875
Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis
Erratum in
-
Errors in the Abstract and Results Section.JAMA Intern Med. 2024 Apr 1;184(4):453. doi: 10.1001/jamainternmed.2024.0643. JAMA Intern Med. 2024. PMID: 38497993 Free PMC article. No abstract available.
Abstract
Importance: Severe hypertriglyceridemia is associated with increased risk of acute pancreatitis. However, the threshold above which triglycerides are associated with acute pancreatitis is unclear.
Objective: To test the hypothesis that nonfasting mild-to-moderate hypertriglyceridemia (177-885 mg/dL; 2-10 mmol/L) is also associated with acute pancreatitis.
Design, setting, and participants: This prospective cohort study examines individuals from the Copenhagen General Population Study in 2003 to 2015 and the Copenhagen City Heart Study initiated in 1976 to 1978 with follow-up examinations in 1981 to1983, 1991 to 1994, and in 2001 to 2003. Median follow-up was 6.7 years (interquartile range, 4.0-9.4 years); and includes 116 550 individuals with a triglyceride measurement from the Copenhagen General Population Study (n = 98 649) and the Copenhagen City Heart Study (n = 17 901). All individuals were followed until the occurrence of an event, death, emigration, or end of follow-up (November 2014), whichever came first.
Exposures: Plasma levels of nonfasting triglycerides.
Main outcomes and measures: Hazard ratios (HRs) for acute pancreatitis (n = 434) and myocardial infarction (n = 3942).
Results: Overall, 116 550 individuals were included in this study (median [interquartile range] age, 57 [47-66] years). Compared with individuals with plasma triglyceride levels less than 89 mg/dL (<1 mmol/L), the multivariable adjusted HRs for acute pancreatitis were 1.6 (95% CI, 1.0-2.6; 4.3 events/10 000 person-years) for individuals with triglyceride levels of 89 mg/dL to 176 mg/dL (1.00 mmol/L-1.99 mmol/L), 2.3 (95% CI, 1.3-4.0; 5.5 events/10 000 person-years) for 177 mg/dL to 265 mg/dL (2.00 mmol/L-2.99 mmol/L), 2.9 (95% CI, 1.4-5.9; 6.3 events/10 000 person-years) for 366 mg/dL to 353 mg/dL (3.00 mmol/L-3.99 mmol/L), 3.9 (95% CI, 1.5-10.0; 7.5 events/10 000 person-years) for 354 mg/dL-442 mg/dL (4.00 mmol/L-4.99 mmol/L), and 8.7 (95% CI, 3.7-20.0; 12 events/10 000 person-years) for individuals with triglyceride levels greater than or equal to 443 mg/dL (≥5.00 mmol/L) (trend, P = 6 × 10-8). Corresponding HRs for myocardial infarction were 1.6 (95% CI, 1.4-1.9; 41 events/10 000 person-years), 2.2 (95% CI, 1.9-2.7; 57 events/10 000 person-years), 3.2 (95% CI, 2.6-4.1; 72 events/10 000 person-years), 2.8 (95% CI, 2.0-3.9; 68 events/10 000 person-years), and 3.4 (95% CI, 2.4-4.7; 78 events/10 000 person-years) (trend, P = 6 × 10-31), respectively. The multivariable adjusted HR for acute pancreatitis was 1.17 (95% CI, 1.10-1.24) per 89 mg/dL (1 mmol/L) higher triglycerides. When stratified by sex, age, education, smoking, hypertension, statin use, study cohort, diabetes, body mass index (calculated as weight in kilograms divided by height in meters squared), alcohol intake, and gallstone disease, these results were similar with no statistical evidence of interaction.
Conclusions and relevance: Nonfasting mild-to-moderate hypertriglyceridemia from 177 mg/dL (2 mmol/L) and above is associated with high risk of acute pancreatitis, with HR estimates higher than for myocardial infarction.
Comment in
-
Hypertriglyceridemia and Pancreatitis-New Evidence That Less Is More.JAMA Intern Med. 2017 May 1;177(5):744-745. doi: 10.1001/jamainternmed.2017.0602. JAMA Intern Med. 2017. PMID: 28460101 No abstract available.
-
Hypertriglyceridemia and Pancreatitis-New Evidence That Less Is More-Reply.JAMA Intern Med. 2017 May 1;177(5):745-746. doi: 10.1001/jamainternmed.2017.0616. JAMA Intern Med. 2017. PMID: 28460108 No abstract available.
Similar articles
-
Low-Grade Inflammation in the Association between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population.Clin Chem. 2019 Feb;65(2):321-332. doi: 10.1373/clinchem.2018.294926. Epub 2018 Dec 5. Clin Chem. 2019. PMID: 30518661
-
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.JAMA. 2007 Jul 18;298(3):299-308. doi: 10.1001/jama.298.3.299. JAMA. 2007. PMID: 17635890
-
Nonfasting triglycerides and risk of ischemic stroke in the general population.JAMA. 2008 Nov 12;300(18):2142-52. doi: 10.1001/jama.2008.621. JAMA. 2008. PMID: 19001625
-
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.Circ Res. 2016 Feb 19;118(4):547-63. doi: 10.1161/CIRCRESAHA.115.306249. Circ Res. 2016. PMID: 26892957 Review.
-
Nonfasting versus fasting lipid profile for cardiovascular risk prediction.Pathology. 2019 Feb;51(2):131-141. doi: 10.1016/j.pathol.2018.09.062. Epub 2018 Dec 3. Pathology. 2019. PMID: 30522787 Review.
Cited by
-
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?Curr Atheroscler Rep. 2024 Nov;26(11):609-615. doi: 10.1007/s11883-024-01236-0. Epub 2024 Oct 23. Curr Atheroscler Rep. 2024. PMID: 39441427 Review.
-
Nanoparticles Fueled by Enzyme for the Treatment of Hyperlipidemic Acute Pancreatitis.ACS Biomater Sci Eng. 2024 Nov 11;10(11):7176-7190. doi: 10.1021/acsbiomaterials.4c00474. Epub 2024 Oct 16. ACS Biomater Sci Eng. 2024. PMID: 39412351
-
New approaches to triglyceride reduction: Is there any hope left?Am J Prev Cardiol. 2024 Mar 22;18:100648. doi: 10.1016/j.ajpc.2024.100648. eCollection 2024 Jun. Am J Prev Cardiol. 2024. PMID: 38584606 Free PMC article.
-
Fibrates and risk of congenital malformations: a nationwide cohort study in South Korea.Arch Gynecol Obstet. 2024 Oct;310(4):1967-1973. doi: 10.1007/s00404-023-07357-2. Epub 2024 Mar 29. Arch Gynecol Obstet. 2024. PMID: 38553644 Free PMC article.
-
Relation among hypertriglyceridaemia, cardiometabolic disease, and hereditary factors-design and rationale of the Stockholm hyperTRIglyceridaemia REGister study.Eur Heart J Open. 2024 Feb 20;4(2):oeae010. doi: 10.1093/ehjopen/oeae010. eCollection 2024 Mar. Eur Heart J Open. 2024. PMID: 38487365 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
